LUHUA WANG to Fatigue
This is a "connection" page, showing publications LUHUA WANG has written about Fatigue.
Connection Strength
0.340
-
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015 Aug 06; 126(6):739-45.
Score: 0.083
-
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood. 2013 Oct 31; 122(18):3122-8.
Score: 0.073
-
Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res. 2013 Apr 15; 19(8):2248-56.
Score: 0.070
-
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012 Sep; 158(6):739-48.
Score: 0.068
-
Recognizing hyperviscosity syndrome in patients with Waldenstrom macroglobulinemia. Clin J Oncol Nurs. 2007 Feb; 11(1):87-95.
Score: 0.046